Ulipristal is classified as a selective progesterone receptor modulator, which is utilized for emergency contraception. It is recommended to be taken within 120 hours of unprotected intercourse, and its primary mode of action is believed to be the inhibition of ovulation.

Selective estrogen receptor modulators are employed in the treatment of breast cancer, osteoporosis, and postmenopausal symptoms.

Progesterone analogs activate receptors in a manner that closely resembles progesterone itself, and are typically included in hormonal contraceptive preparations.

Similarly, estrogen analogs imitate natural estrogen and are commonly found in hormonal contraceptives.

The mechanism of action for levonorgestrel, another frequently used emergency contraceptive, is currently unknown.

Emergency contraception is available in the UK through two methods: emergency hormonal contraception and intrauterine device (IUD). Emergency hormonal contraception includes two types of pills: levonorgestrel and ulipristal. Levonorgestrel works by stopping ovulation and inhibiting implantation, and should be taken as soon as possible after unprotected sexual intercourse (UPSI) for maximum efficacy. The single dose of levonorgestrel is 1.5 mg, but should be doubled for those with a BMI over 26 or weight over 70kg. It is safe and well-tolerated, but may cause vomiting in around 1% of women. Ulipristal, on the other hand, is a selective progesterone receptor modulator that inhibits ovulation. It should be taken within 120 hours after intercourse, and may reduce the effectiveness of hormonal contraception. The most effective method of emergency contraception is the copper IUD, which may inhibit fertilization or implantation. It must be inserted within 5 days of UPSI, or up to 5 days after the likely ovulation date. Prophylactic antibiotics may be given if the patient is at high-risk of sexually transmitted infection. The IUD is 99% effective regardless of where it is used in the cycle, and may be left in-situ for long-term contraception.

Pelvic inflammatory disease is most commonly caused by chlamydia and gonorrhoeae, with gonorrhoeae being the likely cause in this patient since they do not have chlamydia. While HIV does not directly cause pelvic inflammatory disease, it can increase the risk of contracting sexually transmitted infections. Syphilis follows its own distinct clinical course and does not cause pelvic inflammatory disease, while herpes typically presents with painful genital blisters but does not cause pelvic inflammatory disease.

Pelvic inflammatory disease (PID) is a condition where the female pelvic organs, including the uterus, fallopian tubes, ovaries, and surrounding peritoneum, become infected and inflamed. It is typically caused by an infection that spreads from the endocervix. The most common causative organism is Chlamydia trachomatis, followed by Neisseria gonorrhoeae, Mycoplasma genitalium, and Mycoplasma hominis. Symptoms of PID include lower abdominal pain, fever, dyspareunia, dysuria, menstrual irregularities, vaginal or cervical discharge, and cervical excitation.

To diagnose PID, a pregnancy test should be done to rule out an ectopic pregnancy, and a high vaginal swab should be taken to screen for Chlamydia and gonorrhoeae. However, these tests may often be negative, so consensus guidelines recommend having a low threshold for treatment due to the potential complications of untreated PID. Management typically involves oral ofloxacin and oral metronidazole or intramuscular ceftriaxone, oral doxycycline, and oral metronidazole. In mild cases of PID, intrauterine contraceptive devices may be left in, but the evidence is limited, and removal of the IUD may be associated with better short-term clinical outcomes according to recent guidelines.

Complications of PID include perihepatitis (Fitz-Hugh Curtis Syndrome), which occurs in around 10% of cases and is characterized by right upper quadrant pain that may be confused with cholecystitis, infertility (with a risk as high as 10-20% after a single episode), chronic pelvic pain, and ectopic pregnancy.

Placental abruption is suggested by several factors in this scenario, including the woman’s age (which increases the risk), high parity, the onset of clinical shock, and most notably, a tender and hard uterus upon examination. Given the gestational age, an ectopic pregnancy or miscarriage is unlikely, and while placenta previa is a common cause of antepartum hemorrhage, it typically presents with painless vaginal bleeding.

Placental Abruption: Causes, Symptoms, and Risk Factors

Placental abruption is a condition that occurs when the placenta separates from the uterine wall, leading to maternal bleeding into the space between the placenta and the uterus. Although the exact cause of placental abruption is unknown, certain factors have been associated with the condition, including proteinuric hypertension, cocaine use, multiparity, maternal trauma, and increasing maternal age. Placental abruption is relatively rare, occurring in approximately 1 out of 200 pregnancies.

The clinical features of placental abruption include shock that is disproportionate to the visible blood loss, constant pain, a tender and tense uterus, a normal lie and presentation, and absent or distressed fetal heart sounds. Coagulation problems may also occur, and it is important to be aware of the potential for pre-eclampsia, disseminated intravascular coagulation (DIC), and anuria.

In summary, placental abruption is a serious condition that can have significant consequences for both the mother and the fetus. Understanding the risk factors and symptoms of placental abruption is important for early detection and prompt treatment.

LH binds to LH receptors on thecal cells, stimulating the production of androstenedione. This androgen is then converted into oestradiol by aromatase in the granulosa cells.

The process of follicle development can be divided into several stages. Primordial follicles contain an oocyte and granulosa cells. Primary follicles are characterized by the development of the zona pellucida and proliferation of granulosa cells. Pre-antral follicles develop a theca layer. Mature or Graafian follicles are marked by the presence of an antrum. Finally, the corpus luteum forms after the oocyte is released due to enzymatic breakdown of the follicular wall.

It is important to note that FSH, progesterone, testosterone, and oestrogen receptors are not involved in the production of oestradiol from androstenedione.

Anatomy of the Ovarian Follicle

The ovarian follicle is a complex structure that plays a crucial role in female reproductive function. It consists of several components, including granulosa cells, the zona pellucida, the theca, the antrum, and the cumulus oophorus.

Granulosa cells are responsible for producing oestradiol, which is essential for follicular development. Once the follicle becomes the corpus luteum, granulosa lutein cells produce progesterone, which is necessary for embryo implantation. The zona pellucida is a membrane that surrounds the oocyte and contains the protein ZP3, which is responsible for sperm binding.

The theca produces androstenedione, which is converted into oestradiol by granulosa cells. The antrum is a fluid-filled portion of the follicle that marks the transition of a primary oocyte into a secondary oocyte. Finally, the cumulus oophorus is a cluster of cells surrounding the oocyte that must be penetrated by spermatozoa for fertilisation to occur.

Understanding the anatomy of the ovarian follicle is essential for understanding female reproductive function and fertility. Each component plays a unique role in the development and maturation of the oocyte, as well as in the processes of fertilisation and implantation.

Hypergonadotropic hypogonadism occurs when the gonads fail to respond to gonadotropins produced by the anterior pituitary gland. This is commonly seen in Turner’s syndrome, where gonadal dysgenesis leads to low sex steroid levels despite elevated levels of LH and FSH. On the other hand, hypogonadotropic hypogonadism can be caused by Kallmann syndrome, Sheehan’s syndrome, and anorexia nervosa. In Asherman’s syndrome, intrauterine adhesions develop, often due to surgery.

Understanding Infertility: Initial Investigations and Key Counselling Points

Infertility is a common issue that affects approximately 1 in 7 couples. However, it is important to note that around 84% of couples who have regular sex will conceive within 1 year, and 92% within 2 years. The causes of infertility can vary, with male factor accounting for 30%, unexplained causes accounting for 20%, ovulation failure accounting for 20%, tubal damage accounting for 15%, and other causes accounting for the remaining 15%.

To determine the cause of infertility, basic investigations are typically conducted. These include a semen analysis and a serum progesterone test, which is done 7 days prior to the expected next period. The interpretation of the serum progesterone level is as follows: if the level is less than 16 nmol/l, it should be repeated and if it consistently remains low, referral to a specialist is necessary. If the level is between 16-30 nmol/l, it should be repeated, and if it is greater than 30 nmol/l, it indicates ovulation.

In addition to these investigations, there are key counselling points that should be addressed. These include advising the patient to take folic acid, aiming for a BMI between 20-25, and having regular sexual intercourse every 2 to 3 days. Patients should also be advised to quit smoking and limit alcohol consumption.

By understanding the initial investigations and key counselling points for infertility, healthcare professionals can provide their patients with the necessary information and support to help them conceive.

A haemoglobin level of 105 g/L is considered normal at 28 weeks of pregnancy, with the non-pregnant reference range being 115-165 g/L.

During pregnancy, a woman’s body undergoes various physiological changes. The cardiovascular system experiences an increase in stroke volume, heart rate, and cardiac output, while systolic blood pressure remains unchanged and diastolic blood pressure decreases in the first and second trimesters before returning to normal levels by term. The enlarged uterus may cause issues with venous return, leading to ankle swelling, supine hypotension, and varicose veins.

The respiratory system sees an increase in pulmonary ventilation and tidal volume, with oxygen requirements only increasing by 20%. This can lead to a sense of dyspnea due to over-breathing and a fall in pCO2. The basal metabolic rate also increases, potentially due to increased thyroxine and adrenocortical hormones.

Maternal blood volume increases by 30%, with red blood cells increasing by 20% and plasma increasing by 50%, leading to a decrease in hemoglobin levels. Coagulant activity increases slightly, while fibrinolytic activity decreases. Platelet count falls, and white blood cell count and erythrocyte sedimentation rate rise.

The urinary system experiences an increase in blood flow and glomerular filtration rate, with elevated sex steroid levels leading to increased salt and water reabsorption and urinary protein losses. Trace glycosuria may also occur.

Calcium requirements increase during pregnancy, with gut absorption increasing substantially due to increased 1,25 dihydroxy vitamin D. Serum levels of calcium and phosphate may fall, but ionized calcium levels remain stable. The liver experiences an increase in alkaline phosphatase and a decrease in albumin levels.

The uterus undergoes significant changes, increasing in weight from 100g to 1100g and transitioning from hyperplasia to hypertrophy. Cervical ectropion and discharge may increase, and Braxton-Hicks contractions may occur in late pregnancy. Retroversion may lead to retention in the first trimester but usually self-corrects.

During pregnancy, the placenta produces beta-hCG, which helps to sustain the corpus luteum. This, in turn, continues to secrete progesterone and estrogen throughout the pregnancy to maintain the endometrial lining. Eventually, after 6 weeks of gestation, the placenta takes over the production of progesterone.

Endocrine Changes During Pregnancy

During pregnancy, there are several physiological changes that occur in the body, including endocrine changes. Progesterone, which is produced by the fallopian tubes during the first two weeks of pregnancy, stimulates the secretion of nutrients required by the zygote/blastocyst. At six weeks, the placenta takes over the production of progesterone, which inhibits uterine contractions by decreasing sensitivity to oxytocin and inhibiting the production of prostaglandins. Progesterone also stimulates the development of lobules and alveoli.

Oestrogen, specifically oestriol, is another major hormone produced during pregnancy. It stimulates the growth of the myometrium and the ductal system of the breasts. Prolactin, which increases during pregnancy, initiates and maintains milk secretion of the mammary gland. It is essential for the expression of the mammotropic effects of oestrogen and progesterone. However, oestrogen and progesterone directly antagonize the stimulating effects of prolactin on milk synthesis.

Human chorionic gonadotropin (hCG) is secreted by the syncitiotrophoblast and can be detected within nine days of pregnancy. It mimics LH, rescuing the corpus luteum from degenerating and ensuring early oestrogen and progesterone secretion. It also stimulates the production of relaxin and may inhibit contractions induced by oxytocin. Other hormones produced during pregnancy include relaxin, which suppresses myometrial contractions and relaxes the pelvic ligaments and pubic symphysis, and human placental lactogen (hPL), which has lactogenic actions and enhances protein metabolism while antagonizing insulin.

During pregnancy, the depth of breathing increases, which is known as tidal volume. This is caused by progesterone relaxing the intercostal muscles and diaphragm, allowing for greater lung inflation during breathing. This is a normal change and is not caused by oestrogen, which typically causes other physical changes during pregnancy such as spider naevi, palmar erythema, and skin pigmentation.

Other physiological changes that occur during pregnancy include increased uterine size, cervical ectropion, increased vaginal discharge, increased plasma volume, anaemia, increased white blood cell count, platelets, ESR, cholesterol, and fibrinogen, as well as decreased albumin, urea, and creatinine. Progesterone-related effects during pregnancy include decreased blood pressure, constipation, ureteral dilation, bladder relaxation, biliary stasis, and increased tidal volume.

During pregnancy, a woman’s body undergoes various physiological changes. The cardiovascular system experiences an increase in stroke volume, heart rate, and cardiac output, while systolic blood pressure remains unchanged and diastolic blood pressure decreases in the first and second trimesters before returning to normal levels by term. The enlarged uterus may cause issues with venous return, leading to ankle swelling, supine hypotension, and varicose veins.

The respiratory system sees an increase in pulmonary ventilation and tidal volume, with oxygen requirements only increasing by 20%. This can lead to a sense of dyspnea due to over-breathing and a fall in pCO2. The basal metabolic rate also increases, potentially due to increased thyroxine and adrenocortical hormones.

Maternal blood volume increases by 30%, with red blood cells increasing by 20% and plasma increasing by 50%, leading to a decrease in hemoglobin levels. Coagulant activity increases slightly, while fibrinolytic activity decreases. Platelet count falls, and white blood cell count and erythrocyte sedimentation rate rise.

The urinary system experiences an increase in blood flow and glomerular filtration rate, with elevated sex steroid levels leading to increased salt and water reabsorption and urinary protein losses. Trace glycosuria may also occur.

Calcium requirements increase during pregnancy, with gut absorption increasing substantially due to increased 1,25 dihydroxy vitamin D. Serum levels of calcium and phosphate may fall, but ionized calcium levels remain stable. The liver experiences an increase in alkaline phosphatase and a decrease in albumin levels.

The uterus undergoes significant changes, increasing in weight from 100g to 1100g and transitioning from hyperplasia to hypertrophy. Cervical ectropion and discharge may increase, and Braxton-Hicks contractions may occur in late pregnancy. Retroversion may lead to retention in the first trimester but usually self-corrects.

According to research, the contraceptive implant is the most reliable method of birth control, with the exception of abstinence. The intrauterine device (IUD) and depot injections are equally effective as the implant. However, oral contraceptive pills are not as dependable as implanted or injected medications.

Implanon and Nexplanon are both subdermal contraceptive implants that slowly release the hormone etonogestrel to prevent ovulation and thicken cervical mucus. Nexplanon is an updated version of Implanon with a redesigned applicator to prevent deep insertions and is radiopaque for easier location. It is highly effective with a failure rate of 0.07/100 women-years and lasts for 3 years. It does not contain estrogen, making it suitable for women with a history of thromboembolism or migraines. It can be inserted immediately after a termination of pregnancy. However, a trained professional is needed for insertion and removal, and additional contraception is required for the first 7 days if not inserted on days 1-5 of the menstrual cycle.

The main disadvantage of these implants is irregular and heavy bleeding, which can be managed with a co-prescription of the combined oral contraceptive pill. Other adverse effects include headache, nausea, and breast pain. Enzyme-inducing drugs may reduce the efficacy of Nexplanon, and women should switch to a different method or use additional contraception until 28 days after stopping the treatment. Contraindications include ischaemic heart disease/stroke, unexplained vaginal bleeding, past breast cancer, severe liver cirrhosis, and liver cancer. Breast cancer is a UKMEC 4 condition, meaning it represents an unacceptable risk if the contraceptive method is used.

The woman has HELLP syndrome, a severe form of pre-eclampsia. Management includes magnesium sulfate, dexamethasone, blood pressure control, and blood product replacement. Delivery of the fetus is the only cure.

Pre-eclampsia is a condition that occurs during pregnancy and is characterized by high blood pressure, proteinuria, and edema. It can lead to complications such as eclampsia, neurological issues, fetal growth problems, liver involvement, and cardiac failure. Severe pre-eclampsia is marked by hypertension, proteinuria, headache, visual disturbances, and other symptoms. Risk factors for pre-eclampsia include hypertension in a previous pregnancy, chronic kidney disease, autoimmune disease, diabetes, chronic hypertension, first pregnancy, age over 40, high BMI, family history of pre-eclampsia, and multiple pregnancy. To reduce the risk of hypertensive disorders in pregnancy, women with high or moderate risk factors should take aspirin daily. Management involves emergency assessment, admission for severe cases, and medication such as labetalol, nifedipine, or hydralazine. Delivery of the baby is the most important step in management, with timing depending on the individual case.

Pregnancy can be detected through urine tests that identify the beta subunit of the human chorionic gonadotrophin. This hormone increases during the first trimester of pregnancy to support progesterone production by the corpus luteum. Although the alpha subunit of this hormone is identical to that of other hormones, such as luteinising hormone, follicle stimulating hormone, and thyroid stimulating hormone, it is the beta subunit that is recognized and used as a marker for pregnancy. The pituitary gland secretes luteinising hormone and follicle stimulating hormone in all humans, but these hormones are not indicative of pregnancy.

Understanding Ectopic Pregnancy: The Pathophysiology

Ectopic pregnancy occurs when the fertilized egg implants outside the uterus, most commonly in the fallopian tube. In fact, 97% of ectopic pregnancies occur in the tubal region, with the majority in the ampulla. However, if the implantation occurs in the isthmus, it can be more dangerous. The remaining 3% of ectopic pregnancies can occur in the ovary, cervix, or peritoneum.

During ectopic pregnancy, the trophoblast, which is the outer layer of cells that forms the placenta, invades the tubal wall. This invasion can cause bleeding, which may dislodge the embryo. The natural history of ectopic pregnancy includes absorption and tubal abortion, with the latter being the most common. In tubal abortion, the embryo is expelled from the tube, resulting in bleeding and pain. In tubal absorption, the tube may not rupture, and the blood and embryo may be shed or converted into a tubal mole and absorbed. However, if the tube ruptures, it can lead to severe bleeding and potentially life-threatening complications.

In summary, understanding the pathophysiology of ectopic pregnancy is crucial in identifying and managing this potentially life-threatening condition. Early diagnosis and prompt treatment can help prevent complications and improve outcomes for affected individuals.

Breastfeeding has been linked to prolonged neonatal jaundice, which is characterized by high levels of bilirubin in an otherwise healthy breastfed newborn after the first week of life. This type of jaundice lasts longer than normal and has no other identifiable cause. It is important to consider the age at which jaundice appears in order to determine potential underlying causes, such as haemolytic disease, infections, G6PD deficiency, sepsis, polycythaemia, extrahepatic biliary atresia, congenital hypothyroidism, or breastfeeding.

Advantages and Disadvantages of Breastfeeding

Breastfeeding has numerous advantages for both the mother and the baby. For the mother, it promotes bonding with the baby and helps with the involution of the uterus. It also provides protection against breast and ovarian cancer and is a cheap alternative to formula feeding as there is no need to sterilize bottles. However, it should not be relied upon as a contraceptive method as it is unreliable.

Breast milk contains immunological components such as IgA, lysozyme, and lactoferrin that protect mucosal surfaces, have bacteriolytic properties, and ensure rapid absorption of iron so it is not available to bacteria. This reduces the incidence of ear, chest, and gastrointestinal infections, as well as eczema, asthma, and type 1 diabetes mellitus. Breastfeeding also reduces the incidence of sudden infant death syndrome.

One of the advantages of breastfeeding is that the baby is in control of how much milk it takes. However, there are also disadvantages such as the transmission of drugs and infections such as HIV. Prolonged breastfeeding may also lead to nutrient inadequacies such as vitamin D and vitamin K deficiencies, as well as breast milk jaundice.

In conclusion, while breastfeeding has numerous advantages, it is important to be aware of the potential disadvantages and to consult with a healthcare professional to ensure that both the mother and the baby are receiving adequate nutrition and care.

The patient is experiencing secondary amenorrhoea, which is indicative of hypothalamic amenorrhoea due to low-level gonadotrophins. This could be caused by the patient’s intensive training for marathons, as well as other risk factors such as stress and anorexia nervosa. Hyperthyroidism is unlikely as the patient does not exhibit any symptoms or abnormal thyroid function test results. Polycystic ovarian syndrome (PCOS) can be ruled out as the patient does not have hirsutism, a high BMI, or elevated LH and FSH levels. Pregnancy is also not a possibility as the patient’s test was negative and she does not exhibit any signs of pregnancy.

Understanding Amenorrhoea: Causes, Investigations, and Management

Amenorrhoea is a condition characterized by the absence of menstrual periods. It can be classified into two types: primary and secondary. Primary amenorrhoea occurs when menstruation fails to start by the age of 15 in girls with normal secondary sexual characteristics or by the age of 13 in girls with no secondary sexual characteristics. On the other hand, secondary amenorrhoea is the cessation of menstruation for 3-6 months in women with previously normal and regular menses or 6-12 months in women with previous oligomenorrhoea.

The causes of amenorrhoea vary depending on the type. Primary amenorrhoea may be caused by gonadal dysgenesis, testicular feminization, congenital malformations of the genital tract, functional hypothalamic amenorrhoea, congenital adrenal hyperplasia, imperforate hymen, hypothalamic amenorrhoea, polycystic ovarian syndrome, hyperprolactinemia, premature ovarian failure, and thyrotoxicosis. Meanwhile, secondary amenorrhoea may be caused by stress, excessive exercise, PCOS, Sheehan’s syndrome, Asherman’s syndrome, and other underlying medical conditions.

To diagnose amenorrhoea, initial investigations may include pregnancy tests, full blood count, urea & electrolytes, coeliac screen, thyroid function tests, gonadotrophins, prolactin, and androgen levels. Management of amenorrhoea involves treating the underlying cause. For primary amenorrhoea, it is important to investigate and treat any underlying cause. For secondary amenorrhoea, it is important to exclude pregnancy, lactation, and menopause and treat the underlying cause accordingly. Women with primary ovarian insufficiency due to gonadal dysgenesis may benefit from hormone replacement therapy to prevent osteoporosis and other complications.

In conclusion, amenorrhoea is a condition that requires proper diagnosis and management. Understanding the causes and appropriate investigations can help in providing the necessary treatment and care for women experiencing this condition.

During pregnancy, women are checked for anaemia twice – once at the initial booking visit (usually at 8-10 weeks) and again at 28 weeks. The National Institute for Health and Care Excellence (NICE) has set specific cut-off levels to determine if a woman requires oral iron therapy. For the first trimester, the cut-off is less than 110 g/L, for the second and third trimesters, it is less than 105 g/L, and for the postpartum period, it is less than 100 g/L. If a woman falls below these levels, she should receive oral ferrous sulfate or ferrous fumarate. Treatment should continue for three months after iron deficiency is corrected to allow for the replenishment of iron stores.

Haploid cells have one set of chromosomes, diploid cells have two sets, and triploid cells have three sets.

The Process of Spermatogenesis

The process of spermatogenesis is essential for the continuation of our species. It involves diploid mitosis followed by haploid meiosis, resulting in the production of a haploid sperm cell. Unlike females, males have a constant supply of gametes due to the continuous occurrence of spermatogenesis.

Human gametes are haploid cells that contain 23 chromosomes, each of which is individual and one of a pair. Spermatogonial cells undergo constant mitosis, and when they reach the luminal compartment, they become primary spermatocytes. These cells then undergo two stages of meiosis, forming a secondary spermatocyte and then a spermatid. The spermatids migrate to the apex/lumen, where they undergo spermatogenesis, the final maturation and differentiation of the sperm, before being released as sperm cells.

During pregnancy, there is a common occurrence of trace glycosuria due to the increase in glomerular filtration rate and decrease in the reabsorption of filtered glucose in the tubules. This means that glycosuria is not a reliable indicator of diabetes in pregnancy and is considered a normal finding.

Gestational diabetes is characterized by carbohydrate intolerance leading to varying degrees of hyperglycemia during pregnancy. Risk factors include a history of gestational diabetes, obesity, family history of diabetes, previous macrosomia or polyhydramnios, and glycosuria of +1 on multiple occasions or ≥+2 on one occasion. Symptoms include polyhydramnios and glycosuria, and diagnosis is confirmed if fasting glucose levels are >5.6mmol/L or 2-hour oral glucose tolerance test results are >7.8mmol/L.

Pre-diabetes and type 2 diabetes are typically diagnosed before pregnancy. Pre-diabetes is diagnosed with fasting glucose levels of 6.1-6.9 mmol/L or 2-hour oral glucose tolerance test results of 7.8-11.0mmol/L.

During pregnancy, a woman’s body undergoes various physiological changes. The cardiovascular system experiences an increase in stroke volume, heart rate, and cardiac output, while systolic blood pressure remains unchanged and diastolic blood pressure decreases in the first and second trimesters before returning to normal levels by term. The enlarged uterus may cause issues with venous return, leading to ankle swelling, supine hypotension, and varicose veins.

The respiratory system sees an increase in pulmonary ventilation and tidal volume, with oxygen requirements only increasing by 20%. This can lead to a sense of dyspnea due to over-breathing and a fall in pCO2. The basal metabolic rate also increases, potentially due to increased thyroxine and adrenocortical hormones.

Maternal blood volume increases by 30%, with red blood cells increasing by 20% and plasma increasing by 50%, leading to a decrease in hemoglobin levels. Coagulant activity increases slightly, while fibrinolytic activity decreases. Platelet count falls, and white blood cell count and erythrocyte sedimentation rate rise.

The urinary system experiences an increase in blood flow and glomerular filtration rate, with elevated sex steroid levels leading to increased salt and water reabsorption and urinary protein losses. Trace glycosuria may also occur.

Calcium requirements increase during pregnancy, with gut absorption increasing substantially due to increased 1,25 dihydroxy vitamin D. Serum levels of calcium and phosphate may fall, but ionized calcium levels remain stable. The liver experiences an increase in alkaline phosphatase and a decrease in albumin levels.

The uterus undergoes significant changes, increasing in weight from 100g to 1100g and transitioning from hyperplasia to hypertrophy. Cervical ectropion and discharge may increase, and Braxton-Hicks contractions may occur in late pregnancy. Retroversion may lead to retention in the first trimester but usually self-corrects.

If Chlamydia trachomatis is not treated, PID may develop in a significant number of patients. This can lead to serious consequences such as infertility, chronic pain, and ectopic pregnancy caused by scarring.

Pelvic inflammatory disease (PID) is a condition where the female pelvic organs, including the uterus, fallopian tubes, ovaries, and surrounding peritoneum, become infected and inflamed. It is typically caused by an infection that spreads from the endocervix. The most common causative organism is Chlamydia trachomatis, followed by Neisseria gonorrhoeae, Mycoplasma genitalium, and Mycoplasma hominis. Symptoms of PID include lower abdominal pain, fever, dyspareunia, dysuria, menstrual irregularities, vaginal or cervical discharge, and cervical excitation.

To diagnose PID, a pregnancy test should be done to rule out an ectopic pregnancy, and a high vaginal swab should be taken to screen for Chlamydia and gonorrhoeae. However, these tests may often be negative, so consensus guidelines recommend having a low threshold for treatment due to the potential complications of untreated PID. Management typically involves oral ofloxacin and oral metronidazole or intramuscular ceftriaxone, oral doxycycline, and oral metronidazole. In mild cases of PID, intrauterine contraceptive devices may be left in, but the evidence is limited, and removal of the IUD may be associated with better short-term clinical outcomes according to recent guidelines.

Complications of PID include perihepatitis (Fitz-Hugh Curtis Syndrome), which occurs in around 10% of cases and is characterized by right upper quadrant pain that may be confused with cholecystitis, infertility (with a risk as high as 10-20% after a single episode), chronic pelvic pain, and ectopic pregnancy.

Electrolyte imbalances commonly observed in hyperemesis gravidarum include hyponatraemia, hypokalaemia, hypochloraemia, and metabolic alkalosis. This is due to excessive vomiting, which can deplete the body of electrolytes and lead to a loss of hydrogen ions, resulting in metabolic alkalosis. Hyperkalaemia and hypermagnesaemia are unlikely to occur, and hypomagnesaemia is more commonly associated with hyperemesis gravidarum. Metabolic acidosis is not typically seen in this condition.

Hyperemesis gravidarum is a severe form of nausea and vomiting that affects around 1% of pregnancies. It is usually experienced between 8 and 12 weeks of pregnancy but can persist up to 20 weeks. The condition is thought to be related to raised beta hCG levels and is more common in women who are obese, nulliparous, or have multiple pregnancies, trophoblastic disease, or hyperthyroidism. Smoking is associated with a decreased incidence of hyperemesis.

The Royal College of Obstetricians and Gynaecologists recommend that a woman must have a 5% pre-pregnancy weight loss, dehydration, and electrolyte imbalance before a diagnosis of hyperemesis gravidarum can be made. Validated scoring systems such as the Pregnancy-Unique Quantification of Emesis (PUQE) score can be used to classify the severity of NVP.

Management of hyperemesis gravidarum involves using antihistamines as a first-line treatment, with oral cyclizine or oral promethazine being recommended by Clinical Knowledge Summaries. Oral prochlorperazine is an alternative, while ondansetron and metoclopramide may be used as second-line treatments. Ginger and P6 (wrist) acupressure can be tried, but there is little evidence of benefit. Admission may be needed for IV hydration.

Complications of hyperemesis gravidarum can include Wernicke’s encephalopathy, Mallory-Weiss tear, central pontine myelinolysis, acute tubular necrosis, and fetal growth restriction, pre-term birth, and cleft lip/palate (if ondansetron is used during the first trimester). The NICE Clinical Knowledge Summaries recommend considering admission if a woman is unable to keep down liquids or oral antiemetics, has ketonuria and/or weight loss (greater than 5% of body weight), or has a confirmed or suspected comorbidity that may be adversely affected by nausea and vomiting.

Understanding Ovarian Cancer: Risk Factors, Symptoms, and Management

Ovarian cancer is a type of cancer that affects women, with the peak age of incidence being 60 years. It is the fifth most common malignancy in females and carries a poor prognosis due to late diagnosis. Around 90% of ovarian cancers are epithelial in origin, with 70-80% of cases being due to serous carcinomas. Interestingly, recent studies suggest that the distal end of the fallopian tube is often the site of origin of many ‘ovarian’ cancers.

There are several risk factors associated with ovarian cancer, including a family history of mutations of the BRCA1 or the BRCA2 gene, early menarche, late menopause, and nulliparity. Clinical features of ovarian cancer are notoriously vague and can include abdominal distension and bloating, abdominal and pelvic pain, urinary symptoms, early satiety, and diarrhea.

To diagnose ovarian cancer, a CA125 test is usually done initially. If the CA125 level is raised, an urgent ultrasound scan of the abdomen and pelvis should be ordered. However, a CA125 should not be used for screening for ovarian cancer in asymptomatic women. Diagnosis is difficult and usually involves diagnostic laparotomy.

Management of ovarian cancer usually involves a combination of surgery and platinum-based chemotherapy. The prognosis for ovarian cancer is poor, with 80% of women having advanced disease at presentation and the all stage 5-year survival being 46%. It is traditionally taught that infertility treatment increases the risk of ovarian cancer, as it increases the number of ovulations. However, recent evidence suggests that there is not a significant link. The combined oral contraceptive pill reduces the risk (fewer ovulations) as does having many pregnancies.

The most likely cause of the patient’s intractable vomiting during pregnancy is multiple gestation. This condition, known as hyperemesis gravidarum, is characterized by vomiting, dehydration, weight loss, and ketonuria. Multiple gestations can lead to hormone imbalances due to increased levels of βhCG, which can increase vomiting. Risk factors for multiple gestations include the use of fertility-enhancing treatments like IVF and older maternal age. The presence of the placental lambda sign is characteristic of a dichorionic pregnancy.

Complete molar pregnancy is an unlikely diagnosis as it typically presents with abnormal uterine bleeding, pelvic pain, and a snowstorm appearance on ultrasound. Partial molar pregnancy is also unlikely as it is associated with lower levels of βhCG and often has fetal parts present on ultrasound. Physiological vomiting, while common in pregnancy, is not the most likely cause in this case as the patient is experiencing weight loss and ketonuria.

Hyperemesis gravidarum is a severe form of nausea and vomiting that affects around 1% of pregnancies. It is usually experienced between 8 and 12 weeks of pregnancy but can persist up to 20 weeks. The condition is thought to be related to raised beta hCG levels and is more common in women who are obese, nulliparous, or have multiple pregnancies, trophoblastic disease, or hyperthyroidism. Smoking is associated with a decreased incidence of hyperemesis.

The Royal College of Obstetricians and Gynaecologists recommend that a woman must have a 5% pre-pregnancy weight loss, dehydration, and electrolyte imbalance before a diagnosis of hyperemesis gravidarum can be made. Validated scoring systems such as the Pregnancy-Unique Quantification of Emesis (PUQE) score can be used to classify the severity of NVP.

Management of hyperemesis gravidarum involves using antihistamines as a first-line treatment, with oral cyclizine or oral promethazine being recommended by Clinical Knowledge Summaries. Oral prochlorperazine is an alternative, while ondansetron and metoclopramide may be used as second-line treatments. Ginger and P6 (wrist) acupressure can be tried, but there is little evidence of benefit. Admission may be needed for IV hydration.

Complications of hyperemesis gravidarum can include Wernicke’s encephalopathy, Mallory-Weiss tear, central pontine myelinolysis, acute tubular necrosis, and fetal growth restriction, pre-term birth, and cleft lip/palate (if ondansetron is used during the first trimester). The NICE Clinical Knowledge Summaries recommend considering admission if a woman is unable to keep down liquids or oral antiemetics, has ketonuria and/or weight loss (greater than 5% of body weight), or has a confirmed or suspected comorbidity that may be adversely affected by nausea and vomiting.

Anaemia in pregnancy results from a greater increase in plasma volume compared to haemoglobin concentration, leading to a dilution of haemoglobin levels. It is important to note that haemoglobin levels actually increase during pregnancy. Drinking more water does not cause anaemia, as any excess water would be eliminated by the kidneys. Additionally, reduced secretion of ADH does not occur during pregnancy and would result in diuresis rather than anaemia.

During pregnancy, women are checked for anaemia twice – once at the initial booking visit (usually at 8-10 weeks) and again at 28 weeks. The National Institute for Health and Care Excellence (NICE) has set specific cut-off levels to determine if a woman requires oral iron therapy. For the first trimester, the cut-off is less than 110 g/L, for the second and third trimesters, it is less than 105 g/L, and for the postpartum period, it is less than 100 g/L. If a woman falls below these levels, she should receive oral ferrous sulfate or ferrous fumarate. Treatment should continue for three months after iron deficiency is corrected to allow for the replenishment of iron stores.

The ampulla of the fallopian tube is where fertilisation typically takes place.

Following its release from the ovary, the egg travels through the fimbria and into the ampulla. Once ovulation has occurred, the egg can only survive for approximately 24 hours.

Fertilisation predominantly occurs in the ampulla of the fallopian tube. After fertilisation, the resulting embryo remains in the fallopian tube for roughly 72 hours before reaching the end of the tube and being ready for implantation in the uterus.

If implantation happens outside of the uterus, it is referred to as an ectopic pregnancy.

Anatomy of the Uterus

The uterus is a female reproductive organ that is located within the pelvis and is covered by the peritoneum. It is supplied with blood by the uterine artery, which runs alongside the uterus and anastomoses with the ovarian artery. The uterus is supported by various ligaments, including the central perineal tendon, lateral cervical, round, and uterosacral ligaments. The ureter is located close to the uterus, and injuries to the ureter can occur when there is pathology in the area.

The uterus is typically anteverted and anteflexed in most women. Its topography can be visualized through imaging techniques such as ultrasound or MRI. Understanding the anatomy of the uterus is important for diagnosing and treating various gynecological conditions.

When the baby has Rh-positive blood and the mother has Rh-negative blood, their blood supplies can mix during pregnancy. This can lead to the mother producing antibodies that may harm the baby by passing through the placenta and causing conditions like hydrops fetalis. Additionally, subsequent pregnancies may also be impacted.

Rhesus negative mothers can develop anti-D IgG antibodies if they deliver a Rh +ve child, which can cause haemolysis in future pregnancies. Prevention involves testing for D antibodies and giving anti-D prophylaxis at 28 and 34 weeks. Anti-D should also be given in various situations, such as delivery of a Rh +ve infant or amniocentesis. Tests include cord blood FBC, blood group, direct Coombs test, and Kleihauer test. Affected fetuses may experience oedema, jaundice, anaemia, hepatosplenomegaly, heart failure, and kernicterus, and may require transfusions and UV phototherapy.

Androgens play a crucial role in the development of male reproductive organs, as they stimulate the formation of Wolffian ducts that eventually give rise to the vas deferens, epididymis, and seminal vesicles. In the absence of androgen activity, the Wolffian ducts break down, leading to the failure of male reproductive organ development. Additionally, Sertoli cells produce anti-Mullerian hormone, which prevents the formation of female internal genitalia. The lack of androgen effects also results in the absence of masculine characteristics in the external genitalia.

Understanding Androgen Insensitivity Syndrome

Androgen insensitivity syndrome is a genetic condition that affects individuals with an XY genotype, causing them to develop a female phenotype due to their body’s resistance to testosterone. This condition was previously known as testicular feminization syndrome. Common features of this condition include primary amenorrhea, little to no pubic and axillary hair, undescended testes leading to groin swellings, and breast development due to the conversion of testosterone to estrogen.

Diagnosis of androgen insensitivity syndrome can be done through a buccal smear or chromosomal analysis, which reveals a 46XY genotype. After puberty, testosterone levels in individuals with this condition are typically in the high-normal to slightly elevated range for postpubertal boys.

Management of androgen insensitivity syndrome involves counseling and raising the child as female. Bilateral orchidectomy is recommended to reduce the risk of testicular cancer due to undescended testes. Additionally, estrogen therapy may be used to promote the development of secondary sexual characteristics. Understanding androgen insensitivity syndrome is crucial for proper diagnosis and management of affected individuals.

PPH, which is the loss of 500 millilitres or more of blood within 24 hours of delivery, is primarily caused by uterine atony. This occurs when the uterus fails to contract after the placenta is delivered. However, other potential causes must be ruled out through thorough clinical examination. To remember the causes of PPH, the acronym ‘the 4 Ts’ can be used: Tone (uterine atony), Tissue (retained products of conception), Trauma (to the genital tract or perineum), and Thrombin (coagulation abnormalities). This information is based on RCOG Green-top Guideline No. 52.

Postpartum Haemorrhage: Causes, Risk Factors, and Management

Postpartum haemorrhage (PPH) is a condition characterized by excessive blood loss of more than 500 ml after a vaginal delivery. It can be primary or secondary. Primary PPH occurs within 24 hours after delivery and is caused by the 4 Ts: tone, trauma, tissue, and thrombin. The most common cause is uterine atony. Risk factors for primary PPH include previous PPH, prolonged labour, pre-eclampsia, increased maternal age, emergency Caesarean section, and placenta praevia. Management of PPH is a life-threatening emergency that requires immediate involvement of senior staff. The ABC approach is used, and bloods are taken, including group and save. Medical management includes IV oxytocin, ergometrine, carboprost, and misoprostol. Surgical options are considered if medical management fails to control the bleeding. Secondary PPH occurs between 24 hours to 6 weeks after delivery and is typically due to retained placental tissue or endometritis.

Understanding Postpartum Haemorrhage

Postpartum haemorrhage is a serious condition that can occur after vaginal delivery. It is important to understand the causes, risk factors, and management of this condition to ensure prompt and effective treatment. Primary PPH is caused by the 4 Ts, with uterine atony being the most common cause. Risk factors for primary PPH include previous PPH, prolonged labour, and emergency Caesarean section. Management of PPH is a life-threatening emergency that requires immediate involvement of senior staff. Medical management includes IV oxytocin, ergometrine, carboprost, and misoprostol. Surgical options are considered if medical management fails to control the bleeding. Secondary PPH occurs between 24 hours to 6 weeks after delivery and is typically due to retained placental tissue or endometritis. It is important to be aware of the signs and symptoms of PPH and seek medical attention immediately if they occur.

During pregnancy, plasma urea and creatinine levels decrease due to increased renal perfusion, which allows for more efficient clearing of these substances from the circulation. Additionally, the increased plasma volume dilutes these substances. This is a result of physiological changes in pregnancy, such as increased uterine size, cervical ectropion, and increased vaginal discharge. Cardiovascular and haemodynamic changes also occur, including increased plasma volume and decreased levels of albumin, urea, and creatinine. Progesterone-related effects, such as muscle relaxation, can lead to decreased blood pressure, constipation, and bladder relaxation. It is important to note that the foetus does not have functioning kidneys, and the mother filters the blood for it.

During pregnancy, a woman’s body undergoes various physiological changes. The cardiovascular system experiences an increase in stroke volume, heart rate, and cardiac output, while systolic blood pressure remains unchanged and diastolic blood pressure decreases in the first and second trimesters before returning to normal levels by term. The enlarged uterus may cause issues with venous return, leading to ankle swelling, supine hypotension, and varicose veins.

The respiratory system sees an increase in pulmonary ventilation and tidal volume, with oxygen requirements only increasing by 20%. This can lead to a sense of dyspnea due to over-breathing and a fall in pCO2. The basal metabolic rate also increases, potentially due to increased thyroxine and adrenocortical hormones.

Maternal blood volume increases by 30%, with red blood cells increasing by 20% and plasma increasing by 50%, leading to a decrease in hemoglobin levels. Coagulant activity increases slightly, while fibrinolytic activity decreases. Platelet count falls, and white blood cell count and erythrocyte sedimentation rate rise.

The urinary system experiences an increase in blood flow and glomerular filtration rate, with elevated sex steroid levels leading to increased salt and water reabsorption and urinary protein losses. Trace glycosuria may also occur.

Calcium requirements increase during pregnancy, with gut absorption increasing substantially due to increased 1,25 dihydroxy vitamin D. Serum levels of calcium and phosphate may fall, but ionized calcium levels remain stable. The liver experiences an increase in alkaline phosphatase and a decrease in albumin levels.

The uterus undergoes significant changes, increasing in weight from 100g to 1100g and transitioning from hyperplasia to hypertrophy. Cervical ectropion and discharge may increase, and Braxton-Hicks contractions may occur in late pregnancy. Retroversion may lead to retention in the first trimester but usually self-corrects.

The presence of fetal squamous cells in the maternal blood vessels of a woman who died during or after labor suggests that she had amniotic fluid embolism instead of pulmonary thromboembolism.

The patient displayed symptoms of pulmonary embolism shortly after giving birth, including acute shortness of breath, tachycardia, and tachypnea, as well as a wedge-shaped infarction on her chest x-ray. The resulting hypoventilation caused hypoxia. Given that pregnancy is a hypercoagulable state, there is an increased risk of thrombus formation and subsequent embolization, making pulmonary thromboembolism the primary differential diagnosis.

However, the histological findings during autopsy confirmed that the woman had amniotic fluid embolism, as fetal squamous cells were found in her maternal blood vessels. The risk of fetal and maternal blood mixing is highest during the third trimester and delivery, and fetal cells can act as thrombogenic factors. Although rare, this condition has a high mortality rate, and even those who survive often experience severe deficits, including neurological damage.

Fat embolism typically occurs after long bone fractures or orthopedic surgeries, while air embolism is very rare but can cause immediate death. Cholesterol embolization is a common scenario after cannulation, such as angiography, where the catheter mechanically displaces the cholesterol thrombus, leading to emboli.

Amniotic Fluid Embolism: A Rare but Life-Threatening Complication of Pregnancy

Amniotic fluid embolism is a rare but potentially fatal complication of pregnancy that occurs when fetal cells or amniotic fluid enter the mother’s bloodstream, triggering a severe reaction. Although many risk factors have been associated with this condition, such as maternal age and induction of labor, the exact cause remains unknown. It is believed that exposure of maternal circulation to fetal cells or amniotic fluid is necessary for the development of an amniotic fluid embolism, but the underlying pathology is not well understood.

The majority of cases occur during labor, but they can also occur during cesarean section or in the immediate postpartum period. Symptoms of amniotic fluid embolism include chills, shivering, sweating, anxiety, and coughing, while signs include cyanosis, hypotension, bronchospasms, tachycardia, arrhythmia, and myocardial infarction. However, there are no definitive diagnostic tests for this condition, and diagnosis is usually made by excluding other possible causes of the patient’s symptoms.

Management of amniotic fluid embolism requires immediate critical care by a multidisciplinary team, as the condition can be life-threatening. Treatment is primarily supportive, and the focus is on stabilizing the patient’s vital signs and providing respiratory and cardiovascular support as needed. Despite advances in medical care, the mortality rate associated with amniotic fluid embolism remains high, underscoring the need for continued research into the underlying causes and potential treatments for this rare but serious complication of pregnancy.

During the early stages of pregnancy, the corpus luteum is stimulated to secrete progesterone by hCG, which is produced by the syncytiotrophoblast. Pregnancy tests commonly measure hCG levels in urine. This hormone is crucial for maintaining the pregnancy until the placenta is fully developed. The trophoblast is composed of two layers: the cytotrophoblast and the syncytiotrophoblast. The hypoblast is a type of tissue that forms from the inner cell mass, while the epiblast gives rise to the three primary germ layers and extraembryonic mesoderm.

Endocrine Changes During Pregnancy

During pregnancy, there are several physiological changes that occur in the body, including endocrine changes. Progesterone, which is produced by the fallopian tubes during the first two weeks of pregnancy, stimulates the secretion of nutrients required by the zygote/blastocyst. At six weeks, the placenta takes over the production of progesterone, which inhibits uterine contractions by decreasing sensitivity to oxytocin and inhibiting the production of prostaglandins. Progesterone also stimulates the development of lobules and alveoli.

Oestrogen, specifically oestriol, is another major hormone produced during pregnancy. It stimulates the growth of the myometrium and the ductal system of the breasts. Prolactin, which increases during pregnancy, initiates and maintains milk secretion of the mammary gland. It is essential for the expression of the mammotropic effects of oestrogen and progesterone. However, oestrogen and progesterone directly antagonize the stimulating effects of prolactin on milk synthesis.

Human chorionic gonadotropin (hCG) is secreted by the syncitiotrophoblast and can be detected within nine days of pregnancy. It mimics LH, rescuing the corpus luteum from degenerating and ensuring early oestrogen and progesterone secretion. It also stimulates the production of relaxin and may inhibit contractions induced by oxytocin. Other hormones produced during pregnancy include relaxin, which suppresses myometrial contractions and relaxes the pelvic ligaments and pubic symphysis, and human placental lactogen (hPL), which has lactogenic actions and enhances protein metabolism while antagonizing insulin.

During pregnancy, a woman’s body undergoes various physiological changes. The cardiovascular system experiences an increase in stroke volume, heart rate, and cardiac output, while systolic blood pressure remains unchanged and diastolic blood pressure decreases in the first and second trimesters before returning to normal levels by term. The enlarged uterus may cause issues with venous return, leading to ankle swelling, supine hypotension, and varicose veins.

The respiratory system sees an increase in pulmonary ventilation and tidal volume, with oxygen requirements only increasing by 20%. This can lead to a sense of dyspnea due to over-breathing and a fall in pCO2. The basal metabolic rate also increases, potentially due to increased thyroxine and adrenocortical hormones.

Maternal blood volume increases by 30%, with red blood cells increasing by 20% and plasma increasing by 50%, leading to a decrease in hemoglobin levels. Coagulant activity increases slightly, while fibrinolytic activity decreases. Platelet count falls, and white blood cell count and erythrocyte sedimentation rate rise.

The urinary system experiences an increase in blood flow and glomerular filtration rate, with elevated sex steroid levels leading to increased salt and water reabsorption and urinary protein losses. Trace glycosuria may also occur.

Calcium requirements increase during pregnancy, with gut absorption increasing substantially due to increased 1,25 dihydroxy vitamin D. Serum levels of calcium and phosphate may fall, but ionized calcium levels remain stable. The liver experiences an increase in alkaline phosphatase and a decrease in albumin levels.

The uterus undergoes significant changes, increasing in weight from 100g to 1100g and transitioning from hyperplasia to hypertrophy. Cervical ectropion and discharge may increase, and Braxton-Hicks contractions may occur in late pregnancy. Retroversion may lead to retention in the first trimester but usually self-corrects.

Hyperemesis gravidarum (HG) is a condition characterized by persistent vomiting, dehydration, weight loss, and electrolyte imbalance, often accompanied by ketosis. Women with multiple pregnancies are at an increased risk of developing HG due to the higher concentrations of pregnancy-related hormones.

Other risk factors for HG include trophoblastic disease, molar pregnancy, and a history of previous hyperemesis. Hypertension of pregnancy typically occurs after 16 weeks and is not associated with an increased risk of HG.

Large for gestational age is not a risk factor for HG as it is usually diagnosed later in pregnancy during growth scans. Multiparity alone is not a risk factor, but a history of previous hyperemesis or nausea and vomiting during pregnancy increases the risk.

Hyperemesis gravidarum is a severe form of nausea and vomiting that affects around 1% of pregnancies. It is usually experienced between 8 and 12 weeks of pregnancy but can persist up to 20 weeks. The condition is thought to be related to raised beta hCG levels and is more common in women who are obese, nulliparous, or have multiple pregnancies, trophoblastic disease, or hyperthyroidism. Smoking is associated with a decreased incidence of hyperemesis.

The Royal College of Obstetricians and Gynaecologists recommend that a woman must have a 5% pre-pregnancy weight loss, dehydration, and electrolyte imbalance before a diagnosis of hyperemesis gravidarum can be made. Validated scoring systems such as the Pregnancy-Unique Quantification of Emesis (PUQE) score can be used to classify the severity of NVP.

Management of hyperemesis gravidarum involves using antihistamines as a first-line treatment, with oral cyclizine or oral promethazine being recommended by Clinical Knowledge Summaries. Oral prochlorperazine is an alternative, while ondansetron and metoclopramide may be used as second-line treatments. Ginger and P6 (wrist) acupressure can be tried, but there is little evidence of benefit. Admission may be needed for IV hydration.

Complications of hyperemesis gravidarum can include Wernicke’s encephalopathy, Mallory-Weiss tear, central pontine myelinolysis, acute tubular necrosis, and fetal growth restriction, pre-term birth, and cleft lip/palate (if ondansetron is used during the first trimester). The NICE Clinical Knowledge Summaries recommend considering admission if a woman is unable to keep down liquids or oral antiemetics, has ketonuria and/or weight loss (greater than 5% of body weight), or has a confirmed or suspected comorbidity that may be adversely affected by nausea and vomiting.